Literature DB >> 24588297

I heard about it from a friend: assessing interest in buprenorphine treatment.

Aaron D Fox1, Pooja A Shah, Nancy L Sohler, Carolina M Lopez, Joanna L Starrels, Chinazo O Cunningham.   

Abstract

BACKGROUND: In the United States, opioid abuse and dependence continue to be a growing problem, whereas treatment for opioid abuse and dependence remains fairly static. Buprenorphine treatment for opioid dependence is safe and effective but underutilized. Prior research has demonstrated low awareness and use of buprenorphine among marginalized groups. This study investigates syringe exchange participants' awareness of, exposure to, and interest in buprenorphine treatment.
METHODS: Syringe exchange participants were recruited from a mobile unit performing outreach to 9 street-side sites in New York City. Computer-based interviews were conducted to determine (1) opioid users' awareness of, exposure to, and interest in buprenorphine treatment; and (2) the association between awareness or exposure and interest in buprenorphine treatment. Logistic regression models were used to examine the associations between awareness of, direct exposure (i.e., having taken buprenorphine) or indirect exposure (i.e., knowing someone who had taken buprenorphine)S to, and interest in buprenorphine treatment.
RESULTS: Of 158 opioid users, 70% were aware of, 32% had direct exposure to, and 31% had indirect exposure to buprenorphine; 12% had been prescribed buprenorphine. Of 138 opioid users who had never been prescribed buprenorphine, 57% were interested in buprenorphine treatment. In multivariate models, indirect exposure was associated with interest in buprenorphine treatment (adjusted odds ratio [AOR] = 2.65, 95% confidence interval [CI]: 1.22-5.77), but awareness and direct exposure were not.
CONCLUSIONS: Syringe exchange participants were mostly aware of buprenorphine and interested in treatment, but few had actually been prescribed buprenorphine. Because indirect exposure to buprenorphine was associated with interest in treatment, future interventions could capitalize on indirect exposure, such as through peer mentorship, to address underutilization of buprenorphine treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24588297      PMCID: PMC3942801          DOI: 10.1080/08897077.2013.804484

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  42 in total

1.  Ethnic disparities in unmet need for alcoholism, drug abuse, and mental health care.

Authors:  K Wells; R Klap; A Koike; C Sherbourne
Journal:  Am J Psychiatry       Date:  2001-12       Impact factor: 18.112

2.  Individual and social network factors that predict entry to drug treatment.

Authors:  Melissa A Davey; Carl A Latkin; Wei Hua; Karin E Tobin; Steffanie Strathdee
Journal:  Am J Addict       Date:  2007 Jan-Feb

3.  Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence.

Authors:  Andrew A Monte; Todd Mandell; Bonnie B Wilford; Joseph Tennyson; Edward W Boyer
Journal:  J Addict Dis       Date:  2009-07

4.  From research to the real world: buprenorphine in the decade of the Clinical Trials Network.

Authors:  Walter Ling; Petra Jacobs; Maureen Hillhouse; Albert Hasson; Christie Thomas; Thomas Freese; Steven Sparenborg; Dennis McCarty; Roger Weiss; Andrew Saxon; Allan Cohen; Michele Straus; Gregory Brigham; David Liu; Paul McLaughlin; Betty Tai
Journal:  J Subst Abuse Treat       Date:  2010-06

5.  The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.

Authors:  Bradley D Stein; Adam J Gordon; Mark Sorbero; Andrew W Dick; James Schuster; Carrie Farmer
Journal:  Drug Alcohol Depend       Date:  2011-11-16       Impact factor: 4.492

6.  Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Hannah K Knudsen; Amanda J Abraham; J Aaron Johnson; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2009-07-03

Review 7.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

8.  Drug user treatment referrals and entry among participants of a needle exchange program.

Authors:  Elise D Riley; Mahboobeh Safaeian; Steffanie A Strathdee; Robert K Brooner; Peter Beilenson; David Vlahov
Journal:  Subst Use Misuse       Date:  2002       Impact factor: 2.164

9.  Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients.

Authors:  Richard P Mattick; Robert Ali; Jason M White; Susannah O'Brien; Seija Wolk; Cath Danz
Journal:  Addiction       Date:  2003-04       Impact factor: 6.526

10.  Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption.

Authors:  Lori J Ducharme; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2008-11-11
View more
  5 in total

1.  Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes.

Authors:  Andrea Jakubowski; Brianna L Norton; Benjamin T Hayes; Brent E Gibson; Christine Fitzsimmons; L Synn Stern; Franklin Ramirez; Mercedes Guzman; Susan Spratt; Pia Marcus; Aaron D Fox
Journal:  J Addict Med       Date:  2021-11-12       Impact factor: 4.647

2.  Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.

Authors:  Aaron D Fox; Adam Chamberlain; Nancy L Sohler; Taeko Frost; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2014-08-07

3.  Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.

Authors:  Aaron D Fox; Jeronimo Maradiaga; Linda Weiss; Jennifer Sanchez; Joanna L Starrels; Chinazo O Cunningham
Journal:  Addict Sci Clin Pract       Date:  2015-01-16

4.  Development and evaluation of a community-based buprenorphine treatment intervention.

Authors:  Aaron D Fox; Nancy L Sohler; Taeko Frost; Carolina Lopez; Chinazo O Cunningham
Journal:  Harm Reduct J       Date:  2017-05-12

5.  Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.

Authors:  Jamie Carter; Barry Zevin; Paula J Lum
Journal:  Addict Sci Clin Pract       Date:  2019-05-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.